Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients With Pulmonary Sarcoidosis

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients With Pulmonary Sarcoidosis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efzofitimod (Primary)
  • Indications Pulmonary sarcoidosis
  • Focus Adverse reactions; Proof of concept
  • Sponsors aTyr Pharma

    • Most Recent Events

    • 11 Sep 2023 According to an aTyr Pharma media release, this post -hoc analysis from this study were presented in a poster at the European Respiratory Society (ERS) International Congress 2023
    • 11 Sep 2023 Post-hoc data from this study presented in a aTyr Pharma media release.
    • 27 Jun 2023 Number of treatment arms have been increased from 3 to 4 by the addition of Placebo Comparator arm and each arm has been designated for separate dose levels of Efzofitimod, namely 1, 3 and 5 mg/kg.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top